Moderna Rises on Cancer Vaccine Optimism

MRNA stock has risen 9.8% in the last 24 hours to reach 160.40, with its RSI at 71.9, entering overbought territory. The MACD is positive and above the signal line, indicating strong short-term momentum. While optimism around a cancer vaccine supports the news flow, the overbought RSI increases the risk of profit-taking. The price is significantly above its 20-day and 50-day moving averages, indicating an upward trend. In the 1-3 day horizon, the upward bias may persist, but caution is warranted due to the possibility of a correction.

NVAX caught a positive sector-wide sentiment on optimism around Moderna's cancer vaccine and rose 5.88% in the last 24 hours. The price is trading at 10.18, above its 20- and 50-day moving averages, indicating strong short-term momentum. However, the RSI at 69.4 is approaching overbought territory, and the MACD remains in negative territory, below its signal line. Since the news is sector-oriented rather than directly about NVAX, the impact may be limited; nevertheless, positive sentiment could support buying for 1-3 days. Still, due to overbought risk and weak MACD, the upside may be limited.